Does the protein OTUD7B promote the growth of tumors in pancreatic cancer?
OTUD7B is a protein that helps regulate how cells break down other proteins. In pancreatic cancer, research shows that OTUD7B is often found at higher levels than normal, and it helps tumor cells grow, spread, and resist chemotherapy. It does this by stabilizing certain cancer-driving proteins and turning on growth signals inside the cell.
What the research says
Studies have found that OTUD7B is overexpressed in several solid tumors, including pancreatic cancer, and that it promotes tumor cell proliferation, invasion, metastasis, and chemoresistance by stabilizing oncoproteins such as YAP1, ERα, and β-catenin/LEF1, activating pathways like NF-κB, Wnt/β-catenin, and Notch 4. A 2019 study showed that a long noncoding RNA called linc00976 is overexpressed in pancreatic cancer and works by sponging miR-137, which leads to increased OTUD7B expression, and this activates the EGFR/MAPK pathway to promote cancer growth 8. Another 2022 study found that the protein RHBDL2 is highly expressed in pancreatic cancer and interacts with OTUD7B to stabilize N1ICD, a fragment of Notch1, thereby activating the Notch signaling pathway and accelerating cancer cell proliferation and mobility 9. Together, these findings indicate that OTUD7B plays a key role in promoting pancreatic cancer progression through multiple mechanisms.
What to ask your doctor
- Could testing for OTUD7B levels in my tumor help guide treatment decisions?
- Are there any clinical trials targeting OTUD7B or the pathways it activates, such as Notch or EGFR/MAPK?
- How does the presence of OTUD7B relate to my prognosis or potential for resistance to chemotherapy?
- Should I consider genetic testing for related markers like linc00976 or RHBDL2?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.